• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.

作者信息

Schmitz Franz-Josef, Boos Mechthild, Mayer Susanne, Köhrer Karl, Scheuring Sibylle, Fluit Ad C

出版信息

Antimicrob Agents Chemother. 2002 Mar;46(3):934-5. doi: 10.1128/AAC.46.3.934-935.2002.

DOI:10.1128/AAC.46.3.934-935.2002
PMID:11850293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC127515/
Abstract
摘要

相似文献

1
In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.新型去氟（6）喹诺酮BMS-284756对用不同喹诺酮类药物筛选出的肺炎链球菌、化脓性链球菌和金黄色葡萄球菌突变株的体外活性
Antimicrob Agents Chemother. 2002 Mar;46(3):934-5. doi: 10.1128/AAC.46.3.934-935.2002.
2
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.肺炎链球菌、化脓性链球菌和金黄色葡萄球菌对六种喹诺酮类药物的体外耐药性发展情况。
Antimicrob Agents Chemother. 2001 Mar;45(3):938-42. doi: 10.1128/AAC.45.3.938-942.2001.
3
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.DX-619及对照喹诺酮类药物对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.
4
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.新型去氟（6）喹诺酮类药物BMS-284756对金黄色葡萄球菌的活性，包括喹诺酮耐药性突变的作用。
Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21. doi: 10.1128/AAC.46.4.1119-1121.2002.
5
In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.新型非氟化喹诺酮类药物PGE 9262932和PGE 9509924对具有DNA旋转酶和拓扑异构酶IV特定突变的金黄色葡萄球菌和肺炎链球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1651-7. doi: 10.1128/AAC.46.6.1651-1657.2002.
6
Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.新型去氟（6）喹诺酮类药物BMS 284756及七种氟喹诺酮类药物对肺炎链球菌的抗菌活性
Clin Microbiol Infect. 2001 Oct;7(10):572-3.
7
Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.新型去氟（6）喹诺酮BMS-284756对基因明确的金黄色葡萄球菌临床分离株的体外活性增强。
J Antimicrob Chemother. 2002 Feb;49(2):283-7. doi: 10.1093/jac/49.2.283.
8
Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.对去氟-F(6)喹诺酮BMS-284756耐药的肺炎链球菌突变体的筛选及遗传特征分析
Antimicrob Agents Chemother. 2001 Oct;45(10):2865-70. doi: 10.1128/AAC.45.10.2865-2870.2001.
9
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.环丙沙星、氧氟沙星、司帕沙星和曲伐沙星对葡萄球菌和链球菌的杀菌动力学
Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):816-9. doi: 10.1007/s100960050199.
10
Staphylococcus aureus mutants selected by BMS-284756.由BMS-284756筛选出的金黄色葡萄球菌突变体。
Antimicrob Agents Chemother. 2001 Nov;45(11):3273-5. doi: 10.1128/AAC.45.11.3273-3275.2001.

引用本文的文献

1
Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.加替沙星（BMS 284756）对1999年至2001年亚太地区SENTRY项目临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2004 Jun;48(6):2049-55. doi: 10.1128/AAC.48.6.2049-2055.2004.
2
parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513.化脓性链球菌BM4513中赋予环丙沙星耐药性的parC突变。
Antimicrob Agents Chemother. 2002 Nov;46(11):3686-7. doi: 10.1128/AAC.46.11.3686-3687.2002.

本文引用的文献

1
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.肺炎链球菌、化脓性链球菌和金黄色葡萄球菌对六种喹诺酮类药物的体外耐药性发展情况。
Antimicrob Agents Chemother. 2001 Mar;45(3):938-42. doi: 10.1128/AAC.45.3.938-942.2001.
2
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.新型去氟（6）喹诺酮BMS-284756的抗菌谱
Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6. doi: 10.1128/AAC.44.12.3351-3356.2000.
3
Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance.化脓性链球菌临床分离株对多种氟喹诺酮类药物的耐药性：gyrA和parC的鉴定以及与耐药相关的点突变特征分析
Antimicrob Agents Chemother. 2000 Nov;44(11):3196-8. doi: 10.1128/AAC.44.11.3196-3198.2000.
4
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.1997 - 1998呼吸道疾病流行季期间，来自全球监测研究的对不同氟喹诺酮类药物敏感性降低的肺炎链球菌临床分离株中gyrA、gyrB、parC和parE基因突变的发生率。
Antimicrob Agents Chemother. 2000 Feb;44(2):462-6. doi: 10.1128/AAC.44.2.462-466.2000.
5
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.吉米沙星与其他九种药物的抗肺炎球菌活性比较。
Antimicrob Agents Chemother. 2000 Feb;44(2):304-10. doi: 10.1128/AAC.44.2.304-310.2000.
6
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.新型去-F(6)-喹诺酮T-3811ME的体外和体内抗菌活性
Antimicrob Agents Chemother. 1999 May;43(5):1077-84. doi: 10.1128/AAC.43.5.1077.
7
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.116株不相关金黄色葡萄球菌分离株中grlA、grlB、gyrA和gyrB基因突变特征及突变对环丙沙星最低抑菌浓度的影响
Antimicrob Agents Chemother. 1998 May;42(5):1249-52. doi: 10.1128/AAC.42.5.1249.